Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study

Alves, Natália Ribeiro de Magalhães; Kurizky, Patrícia Shu; Mota, Licia Maria Henrique da; Albuquerque, Cleandro Pires de; Esper, Juliana Tomaz; Campos, Aridne Souza Costa; Reis, Vitoria Pereira; Ferro, Henrique Metzker; Gil-Jaramillo, Natalia; Brito-de-Sousa, Joaquim Pedro; Leal, Luana Cabral Leão; Nóbrega, Otávio de Toledo; Araújo, Carla Nunes de; Santos Júnior, Agenor de Castro Moreira dos; Martins, Gladys Aires; Martins Filho, Olindo Assis; Gomes, Ciro Martins.
An. bras. dermatol ; 99(1): 34-42, Jan.-Feb. 2024. tab, graf
Artigo em Inglês | LILACS-Express | ID: biblio-1527686

Documentos relacionados

  1. Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study.
  2. A novel online calculator based on clinical features and hematological parameters to predict total skin clearance in patients with moderate to severe psoriasis.
  3. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
  4. Blocking interleukin-17 in psoriasis: Real-world experience from the PsoPlus cohort.
  5. [Hand eczema or psoriasis: update on the FB 323 study occupational dermatology cohort].
  6. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
  7. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry.
  8. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
  9. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
  10. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.